Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity-Reference-Cited by-同舟云学术

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

Published:2019-06-10 Issue:2 Volume:50 Page:193-203
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Newsome Philip¹²^ORCID,Francque Sven³,Harrison Stephen⁴,Ratziu Vlad⁵,Van Gaal Luc⁶,Calanna Salvatore⁷,Hansen Morten⁷,Linder Martin⁷,Sanyal Arun⁸^ORCID

Affiliation:

1. National Institute for Health Research Birmingham Biomedical Research Centre and Liver Unit at University Hospitals Birmingham NHS Foundation Trust; Birmingham UK

2. Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy; University of Birmingham; Birmingham UK

3. Department of Gastroenterology and Hepatology; Antwerp University Hospital; Edegem, Antwerp Belgium

4. Radcliffe Department of Medicine; University of Oxford; Oxford UK

5. ICAN - Institute for Cardiometabolism and Nutrition; Hôpital Pitié Salpêtrière, Sorbonne University; Paris France

6. Department of Endocrinology, Diabetology and Metabolism; Antwerp University Hospital; Edegem, Antwerp Belgium

7. Novo Nordisk A/S; Søborg Denmark

8. Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine; Virginia Commonwealth University; Richmond Virginia

Funder

Novo Nordisk

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15316/fullpdf

Reference59 articles.

1. The global NAFLD epidemic;Loomba;Nat Rev Gastroenterol Hepatol,2013

2. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort;Setiawan;Hepatology,2016

3. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

4. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome;Marchesini;Diabetes,2001

5. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease;Wang;Exp Ther Med,2013

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

2. Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes;Cureus;2024-08-27

3. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19

4. Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial;Diseases;2024-08-17

5. Current strategies for nonalcoholic fatty liver disease treatment (Review);International Journal of Molecular Medicine;2024-08-08